However, preclinical models of NASH-induced HCC demonstrated that increased hepatic CD8 and PD-1 induced by immunotherapy impair immune surveillance without tumor regression, highlighting the need for predictive biomarkers for ICI efficacy [19]. Here, CD8A is linked to metabolic dysfunction-associated steatohepatitis.